Manas AI

Established in 2025 and based in New York, US, Manas AI operates as a biopharmaceutical company that develops therapeutic medicine for cancer. Manas AI primarily serves pharmaceutical companies and research institutions globally, with a strategic focus on key markets in North America, Europe, and Asia. Manas AI specializes in advanced artificial intelligence and generative computational chemistry for drug discovery and development, with a primary focus on oncology and rare diseases such as triple-negative breast cancer, prostate cancer, and lymphoma. The company's core offerings include chemical libraries and proprietary AI filters that identify high-potential therapeutic candidates. Their platform, built on Microsoft’s Azure cloud infrastructure, enables molecular docking processes to occur at speeds up to 100 times faster than traditional methods, to accelerate the discovery of chemical entities by mapping the fundamental rules of drug binding.  Manas AI operates primarily on a B2B business model, engaging in partnerships and collaborations with pharmaceutical companies and research organizations to facilitate drug development processes. Its revenue generation is structured around service agreements that include project-based fees for AI-driven drug discovery services, as well as potential subscription models for access to proprietary platforms and libraries.

1. Seed

   Sep 23, 2025

   Amount

   $26M

   Investors

   Locked

2. Seed

   Jan 27, 2025

   Amount

   $25M

   Investors

   Locked